In women with inflammatory bowel diseases (IBDs), exposure to immunomodulator or biologic therapy has not been associated with adverse events during pregnancy or outcomes of newborns.
Dr Ashwin Ananthakrishnan and colleagues from Massachusetts, USA investigated whether exposure of patients to these agents during pregnancy affects serologic responses to vaccines in newborns.
The researchers collected data from the Pregnancy in IBD and Neonatal Outcomes registry, which records outcomes of pregnant women with diagnosis of IBD receiving care at multiple centers in the United States, from 2007 through 2016.
Serum samples collected from infants at least 7 months old were analyzed for titers of antibodies to Haemophilus influenzae B (HiB) or tetanus toxin.
|There was no difference in the proportion of infants with protective antibody titers to tetanus toxoid|
|Clinical Gastroenterology & Hepatology|
Mothers completed a survey of vaccine practices and outcomes from 2013 through 2016.
Umbilical cord blood samples from 33 infants were assayed for concentration of biologic agents.
The team compared vaccination response between infants born to mothers exposed to biologic therapy and infants born to unexposed mothers.
A total of 179 women completed the vaccine survey.
The researchers found no significant difference in proportions of infants with protective antibody titers against HiB born to exposed mothers vs unexposed mothers.
The research team also found no difference in the proportion of infants with protective antibody titers to tetanus toxoid born to exposed mothers vs unexposed mothers.
The team noted that median concentration of infliximab in cord blood did not differ significantly between infants with vs without protective antibody titers to HiB or tetanus toxoid.
Mild reactions were observed in 7/40 infants who received rotavirus vaccine and whose mothers had been exposed to biologic therapies.
Dr Ananthakrishnan's team concludes, "Vaccination of infants against HiB and tetanus toxin, based on antibody titers measured when infants were at least 7 months old, does not appear to be affected by in utero exposure to biologic therapy."